Industry News

Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company, today announced that it acquired the U.S. and Canadian rights to ZONTIVITY ®, pursuant to an asset purchase agreement entered into between Merck, known as MSD outside the United States and Canada, and Aralez..."/>
Aralez Acquires United States And Canadian Rights To ZONTIVITY From Merck
NantHealth’ s decision support, patient engagement, care coordination, and analytics solutions to help Phoenix Children’ s advance population health and improve value-based outcomes. CULVER CITY, Calif.---- NantHealth, Inc.,, a leading next-generation, evidence-based,..."/>
Phoenix Children’s Hospital Selects NantHealth’s Molecular Testing Platform and Comprehensive Suite of Software Solutions for Precision Cancer Care
CryoLife, Inc., a leading medical device and tissue processing company focused on cardiac surgery, announced today that it will participate in the upcoming Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016 in New York. A live webcast of the Company's presentation is scheduled to begin at 4:40 p.m. ET and will feature an overview of the company and a fireside chat with Pat Mackin, Chairman, President and Chief Executive..."/>
CryoLife to Present at Morgan Stanley Global Healthcare Conference
Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company, today announced that it acquired the U.S. and Canadian rights to ZONTIVITY ®, pursuant to an asset purchase agreement entered into between Merck, known as MSD outside the United States and Canada, and Aralez..."/>
Aralez Acquires United States And Canadian Rights To ZONTIVITY From Merck
Cerus Corporation announced today that it has granted stock options and restricted stock units to Vivek K. Jayaraman, Cerus’ newly appointed chief commercial officer. These awards were granted pursuant to the Cerus Corporation Inducement Plan, approved by the Compensation Committee of Cerus’ Board of Directors and granted as an inducement material to Mr. Jayaraman’ s employment with Cerus, in accordance with NASDAQ Listing Rule 5635 (c)."/>
Cerus Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company developing vascular disrupting agents for the treatment of orphan oncology indications, today announced it will be featured as a presenting company at the 18 th Annual Rodman& Renshaw Global Investment Conference. Mateon’ s presentation will take place on Monday, September 12, 2016 at 12:30 p.m. Eastern time in the Louis Salon at the Lotte New York Palace Hotel.."/>
Mateon Therapeutics to Present at the 18th Annual Rodman and Renshaw Global Investment Conference in New York on September 12, 2016
International Stem Cell Corporation, a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, today announced that it will present at the 18th Annual Rodman& Renshaw Global Investment Conference.. Russell Kern, PhD., ISCO’ s executive vice president& chief scientific officer will provide an update on the company and the clinical trial currently underway. ISCO’ s management team will be..."/>
International Stem Cell Corporation to Present at the 18th Annual Rodman and Renshaw Global Investment Conference
Evoke Pharma, Inc., a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, today announced that it has completed a pre? New Drug Application meeting with the U.S. Food and Drug Administration regarding its lead product candidate, Gimoti™, its patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adult women."/>
Evoke Pharma Announces Positive Non-Clinical Pre-NDA Meeting with FDA for Gimoti
Skyline Medical Inc., developer of the innovative STREAMWAY ® waste fluid disposal system for medical applications, is issuing a reminder that it will hold a business update conference call on Thursday, September 8, 2016 to discuss its proposed joint venture with Electronic On-Ramp and other corporate activities, and its upcoming Special Meeting of Stockholders to be held on September 15, 2016.. The conference call is scheduled to begin at..."/>
Skyline Medical to Hold Business Update Conference Call on September 8th
Align Technology, Inc., the worldwide market leader in clear aligner treatment, today announced that 4 million patients have now started treatment with Invisalign, the most technically advanced clear aligner system in the world. This is a significant accomplishment for the company and the 100,000 Invisalign-trained doctors around the world, demonstrating increased global acceptance of Invisalign treatment as a preferred..."/>
Align Technology Reaches 4 Millionth Invisalign Patient; Pace of Adoption Accelerating Worldwide
Progenics Pharmaceuticals, Inc., an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced the appointment of Bryce V. Tenbarge as Vice President of Commercial, effective August 22, 2016. In this newly created role, Mr. Tenbarge will report to Mark Baker, Chief Executive Officer of Progenics, and will be responsible for leading all of the Company’ s commercial activities."/>
Progenics Pharmaceuticals Announces Appointment of Bryce V. Tenbarge as Vice President of Commercial
Pieris Pharmaceuticals, Inc., a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for cancer and other diseases, announced today that it will be presenting a poster at the 2016 CRI-CIMT-AACR International Cancer Immunotherapy Conference- Translating Science into Survival, taking place in New York City, September 25-26, 2016.. The poster entitled "Costimulatory T-cell..."/>
Pieris Pharmaceuticals Announces Presentation of Data for Its Lead IO Bispecific Program, PRS-343, at the 2016 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
Tobira Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis and other liver diseases, today announced that Laurent Fischer, M.D., the company’ s chief executive officer, has been appointed to serve on the Liver Forum’ s steering committee. The steering committee provides overall scientific leadership to the Liver Forum. The goal of the Liver Forum..."/>
Tobira Therapeutics Announces Appointment of Dr. Laurent Fischer as Industry Co-chair of the Liver Forum Steering Committee
Opexa Therapeutics, Inc., a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, today announced that Neil K. Warma, President and Chief Executive Officer, will present at the Rodman& Renshaw 18th Annual Global Investment Conference on Monday, September 12, 2016, at 4:15 p.m. EDT in the Kennedy II room of the Lotte New York Palace Hotel in New York City. Warma will provide an update on the Abili-T Trial, the..."/>
Opexa Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference
Medidata and Techfields Launch mHealth Stroke Study
Rosetta Genomics Ltd., a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that the Company’ s first-of-its-kind microRNA classifier for indeterminate thyroid nodules, RosettaGX Reveal™, is now available to be utilized on ThinPrep ® samples."/>
RosettaGX Reveal™ Thyroid miRNA Classifier Now Available to Be Utilized on ThinPrep® Samples
Cerus Corporation announced today that William“ Obi” Greenman, Cerus’ president and chief executive officer, is scheduled to present a corporate update at the Morgan Stanley Healthcare Conference at 1:00PM ET on Wednesday, September 14, 2016.. A live webcast of the presentation will be available from the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approximately two weeks following the completion..."/>
Cerus to Present at the Morgan Stanley Global Healthcare Conference on September 14, 2016
Chemed Corporation today announced that it will deliver a presentation at the Morgan Stanley Global Healthcare Conference on Wednesday, September 14, 2016, at approximately 1:00 p.m. at The Grand Hyatt Hotel in New York City. The audio webcast can be accessed by visiting the Chemed website at www.chemed.com. The webcast replay will be available within 24 hours after the live presentation and will be accessible for 90 days."/>
Chemed Corporation to Present at the Morgan Stanley Global Healthcare Conference
Blueprint Medicines Corporation, a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today announced that Jeff Albers, Blueprint Medicines' Chief Executive Officer, will present a company overview at the Morgan Stanley Global Healthcare Conference on Wednesday, September 14, 2016 at 11:40 a.m. ET. A live webcast of the presentation will be available by visiting..."/>
Blueprint Medicines to Present at Morgan Stanley Global Healthcare Conference
Relmada Therapeutics, Inc., a clinical-stage company developing novel therapies for the treatment of central nervous system diseases, today announced that the Company will present at the Rodman& Renshaw 18th Annual Global Investment Conference on being held September 11-13, 2016 at the Lotte New York Palace Hotel. The presentation by Sergio Traversa, Chief Executive Officer of Relmada Therapeutics, is scheduled to begin at 12:05 p.m...."/>
Relmada Therapeutics to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
Sensus Healthcare, Inc., a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions such as keloids with superficial radiation therapy, announced today it has been named the winner of the Frost& Sullivan 2016 Global Non-melanoma Skin Cancer Therapy Technology Leadership Award for its innovative therapy treatment technology. Sensus Healthcare scored an average 9.5 out of 10 possible..."/>
Sensus Healthcare, Inc. Receives the Frost & Sullivan 2016 Global Non-melanoma Skin Cancer Therapy Technology Leadership Award
Cogentix Medical, Inc., a medical device company that develops, manufactures and markets innovative proprietary products for the urology market, today announced that it has entered into a securities purchase agreement with Accelmed Growth Partners, L.P. Under the terms of the securities purchase agreement, Accelmed would purchase $25 million of Cogentix Medical common stock from the Company at $1.55 per share, a 29% premium over the..."/>
Cogentix Medical Enters Into Definitive Agreement For $25 Million Equity Investment
DelMar Pharmaceuticals, Inc., a company focused on developing and commercializing proven cancer therapies in new orphan drug indications, and Accurexa Inc., a company focused on the development of novel neurological therapies to be directly delivered into the brain, announced today a collaboration to develop a novel formulation for the local delivery of combination chemotherapy for the treatment..."/>
DelMar Pharmaceuticals and Accurexa to Collaborate in the Development of a Novel Combination Chemotherapy for the Local Treatment of Brain Cancer

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology544 Articles
Consumer Discretionary483 Articles
Financials312 Articles
Industrials304 Articles
Health Care270 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.